Table 2.

Clinical trial study design.

Study arm	Number of subjects in per protocol population	Vaccine	Vaccination schedulea
			Day 0 SC (mL)	Day 14 SC (mL)	Day 28 SC (mL)	6 Months IM (mL)
A	67	Full-Dose AVA	0.50	0.50	NA	0.50
B	59	Full-Dose AVA	0.50	NA	0.50	0.50
C	59	Full-Dose AVA	0.50	0.50	0.50	0.50
D	60	Half-Dose AVA	0.25	0.25	0.25	0.50
Total	245

SC – Subcutaneous.

IM – Intramuscular.

NA – Not applicable.

^aOnly data through Day 28 included in analysis.